SILENCE THERAPEUTICS PLC-ADR (SLN) Stock Overview
USA - NASDAQ:SLN - US82686Q1013 - ADR
SLN Key Statistics, Chart & Performance
The current stock price of SLN is 7.31 USD. In the past month the price increased by 41.76%. In the past year, price decreased by -59.11%.
SLN Latest News, Press Relases and Analysis
SLN Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 21.55 | 403.13B | ||
| AMGN | AMGEN INC | 13.39 | 157.20B | ||
| GILD | GILEAD SCIENCES INC | 15.3 | 146.96B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.79 | 107.66B | ||
| REGN | REGENERON PHARMACEUTICALS | 14.53 | 69.32B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 58.93B | ||
| ARGX | ARGENX SE - ADR | 89.07 | 50.51B | ||
| INSM | INSMED INC | N/A | 41.05B | ||
| ONC | BEONE MEDICINES LTD-ADR | 4.96 | 33.85B | ||
| NTRA | NATERA INC | N/A | 26.52B | ||
| BNTX | BIONTECH SE-ADR | N/A | 25.16B | ||
| BIIB | BIOGEN INC | 9.34 | 21.93B |
Related stock screener links
About SLN
Company Profile
Silence Therapeutics PLC is a GB-based company operating in Biotechnology industry. Silence Therapeutics plc is a global clinical-stage biotechnology company engaged in transforming people’s lives by silencing diseases through precision-engineered medicines created with proprietary siRNA (short interfering RNA) technology. The firm leverages its mRNAi GOLD platform to create siRNAs designed to precisely target and silence disease-associated genes in the liver. The firm focuses on areas of high unmet medical need with programs advancing cardiovascular disease, hematology and rare diseases. Divesiran (SLN124) is its wholly owned siRNA product candidate designed to inhibit TMPRSS6 expression in the liver. Zerlasiran is a siRNA molecule designed for the treatment of cardiovascular disease associated with elevated Lp(a), a lipoprotein in the blood. In addition to its wholly owned clinical pipeline, it has a third siRNA product candidate from its mRNAi GOLD platform in Phase I development in an undisclosed indication through its collaboration with AstraZeneca.
Company Info
SILENCE THERAPEUTICS PLC-ADR
72 Hammersmith Road
London W14 8TH GB
CEO: Mark Rothera
Employees: 116
Phone: 442034576900
SILENCE THERAPEUTICS PLC-ADR / SLN FAQ
What does SLN do?
Silence Therapeutics PLC is a GB-based company operating in Biotechnology industry. Silence Therapeutics plc is a global clinical-stage biotechnology company engaged in transforming people’s lives by silencing diseases through precision-engineered medicines created with proprietary siRNA (short interfering RNA) technology. The firm leverages its mRNAi GOLD platform to create siRNAs designed to precisely target and silence disease-associated genes in the liver. The firm focuses on areas of high unmet medical need with programs advancing cardiovascular disease, hematology and rare diseases. Divesiran (SLN124) is its wholly owned siRNA product candidate designed to inhibit TMPRSS6 expression in the liver. Zerlasiran is a siRNA molecule designed for the treatment of cardiovascular disease associated with elevated Lp(a), a lipoprotein in the blood. In addition to its wholly owned clinical pipeline, it has a third siRNA product candidate from its mRNAi GOLD platform in Phase I development in an undisclosed indication through its collaboration with AstraZeneca.
Can you provide the latest stock price for SILENCE THERAPEUTICS PLC-ADR?
The current stock price of SLN is 7.31 USD. The price increased by 1.11% in the last trading session.
What is the dividend status of SILENCE THERAPEUTICS PLC-ADR?
SLN does not pay a dividend.
How is the ChartMill rating for SILENCE THERAPEUTICS PLC-ADR?
SLN has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 0 out of 10.
What sector and industry does SILENCE THERAPEUTICS PLC-ADR belong to?
SILENCE THERAPEUTICS PLC-ADR (SLN) operates in the Health Care sector and the Biotechnology industry.
Should I buy SLN stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on SLN.
SLN Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to SLN. When comparing the yearly performance of all stocks, SLN is a bad performer in the overall market: 89.1% of all stocks are doing better.
SLN Financial Highlights
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | N/A |